Antidepressants
Agency approves new antidepressant for adults
Published in Medical Letter on the CDC and FDA, August 29th, 2004
Maker Eli Lilly & Co. is banking on Cymbalta as a successor to its once-blockbuster Prozac. Cymbalta, known chemically as duloxetine, is one of a newer class of antidepressants that targets two brain chemicals involved in depression, serotonin and norepinephrine.
It's the first antidepressant to hit the market since the Food and Drug Administration (FDA) began investigating whether such drugs can sometimes increase the risk of suicide, particularly when used by teenagers, or if patients' underlying depression is to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- AIDS/HIV Diagnosis
IgG-capture BED-enzyme immunoassay detects recent HIV seroconversion - Outbreaks
Norovirus causing gastroenteritis on cruise ships identified - Rubella Vaccine
Rubella vaccination strategy for women of childbearing age developed - Toxicology
CDC makes advances in identifying and measuring chemical agents in humans - Ultrasound
Ultrasonography causes temperature rise at bone/soft-tissue interface - AIDS/HIV Diagnosis
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System reviewed - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
